Blis.Ns

BLIS.NS maintains a strong liquidity position with a current ratio of 4.77, indicating that the company has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which raises some liquidity concerns. The company's debt-to-equity ratio is 0.08, suggesting a conservative capital structure with minimal reliance on debt financing.

In terms of profitability, BLIS.NS reports a return on equity (ROE) of 8.03% and a return on assets (ROA) of 6.48%, both of which are in line with industry norms for pharmaceutical companies. The company's operating income of INR 972.66 million and net income of INR 842.99 million reflect a healthy margin, although the gross profit margin of 47.5% is slightly below the industry median.

The company's revenue is primarily concentrated in India, with no significant international operations disclosed in the available data. This geographic concentration may expose the company to regulatory and economic risks specific to the Indian market. The company's revenue segments are not explicitly detailed in the input data, but the business is primarily focused on pharmaceutical products.

BLIS.NS has demonstrated consistent revenue growth, with a total revenue of INR 8,097.26 million in the latest reporting period. The company's capital expenditures were negative at INR -762.86 million, indicating a reduction in investment in physical assets, which may signal a shift in strategic focus or a cost-cutting initiative. The outlook for the next fiscal year is positive, with expected revenue growth and stable operating margins.

The company's risk profile is characterized by medium liquidity risk and low dilution potential. The risk assessment highlights the negative net cash position as a key flag, but the company's low debt levels and strong equity base mitigate the overall financial risk. No significant dilution events are expected in the near term, and the company's share count has remained stable.

Recent filings and transcripts do not indicate any major corporate events or strategic shifts. The company's focus remains on maintaining profitability and managing its capital structure efficiently.